This database contains 175 studies, archived under the term: "administration & dosage"
Click here to filter this large number of results.
Virgin olive oil supplementation and long-term cognition: the PREDIMED-NAVARRA randomized, trial
Martínez-Lapiscina, Elena H,
Clavero, P.,
Toledo, E.,
San Julian, B.,
Sanchez-Tainta, A.,
Corella, D.,
Lamuela-Raventos, R. M.,
Martinez, J. A.,
Martinez-Gonzalez, M. Á.
Objective: To assess the effect on cognition of a controlled intervention testing Mediterranean diets (MedDiet).; Design: Randomized trial after 6.5 years of nutritional intervention.; Setting: Eight primary care centers affiliated to the University of Navarra.; Participants: A random subsample of 285 participants (95 randomly allocated to each of 3 groups) of the PREDIMED-NAVARRA trial. All […]
Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials
Manson, JoAnn E.,
Chlebowski, Rowan T.,
Stefanick, Marcia L.,
Aragaki, Aaron K.,
Rossouw, Jacques E.,
Prentice, Ross L.,
Anderson, Garnet,
Howard, Barbara V.,
Thomson, Cynthia A.,
LaCroix, Andrea Z.,
Wactawski-Wende, Jean,
Jackson, Rebecca D.,
Limacher, Marian,
Margolis, Karen L.,
Wassertheil-Smoller, Sylvia,
Beresford, Shirley A.,
Cauley, Jane A.,
Eaton, Charles B.,
Gass, Margery,
Hsia, Judith,
Johnson, Karen C.,
Kooperberg, Charles,
Kuller, Lewis H.,
Lewis, Cora E.,
Liu, Simin,
Martin, Lisa W.,
Ockene, Judith K.,
O’Sullivan, Mary Jo,
Powell, Lynda H.,
Simon, Michael S.,
Van Horn, Linda,
Vitolins, Mara Z.,
Wallace, Robert B.
Importance: Menopausal hormone therapy continues in clinical use but questions remain regarding its risks and benefits for chronic disease prevention.; Objective: To report a comprehensive, integrated overview of findings from the 2 Women’s Health Initiative (WHI) hormone therapy trials with extended postintervention follow-up.; Design, Setting, and Participants: A total of 27,347 postmenopausal women aged 50 […]
The effect of an aloe polymannose multinutrient complex on cognitive and immune functioning in Alzheimer’s disease
Lewis, John E.,
McDaniel, H. Reginald,
Agronin, Marc E.,
Loewenstein, David A.,
Riveros, Jorge,
Mestre, Rafael,
Martinez, Mairelys,
Colina, Niurka,
Abreu, Dahlia,
Konefal, Janet,
Woolger, Judi M.,
Ali, Karriem H.
Alzheimer’s disease (AD) is a leading killer of Americans, imparts a significant toll on the quality of life of the patient and primary caregiver, and results in inordinate costs in an already overburdened medical system. Prior studies on cholinesterase inhibitors among AD patients have shown minimal amelioration of disease symptoms and/or restoration of lost cognitive […]
Effect of methylphenidate on attention in apathetic AD patients in a randomized, placebo-controlled trial
Lanctôt, Krista L.,
Chau, Sarah A.,
Herrmann, Nathan,
Drye, Lea T.,
Rosenberg, Paul B.,
Scherer, Roberta W.,
Black, Sandra E.,
Vaidya, Vijay,
Bachman, David L.,
Mintzer, Jacobo E.
Background: Little is known about the effect of methylphenidate (MPH) on attention in Alzheimer’s disease (AD). MPH has shown to improve apathy in AD, and both apathy and attention have been related to dopaminergic function. The goal was to investigate MPH effects on attention in AD and assess the relationship between attention and apathy responses.; […]
A multicenter, open-label, 24-week follow-up study for efficacy on cognitive function of donepezil in Binswanger-type subcortical vascular dementia
Jay Cheol Kwon,,
Eung Gyu Kim,,
Jae Woo Kim,,
Oh Dae Kwon,,
Bong Goo Yoo,,
Hyon Ah Yi,,
Nack Cheon Choi,,
Seon Young Ahn,,
Byung Hwa Lee,,
Myong Jin Kang,,
Dae Seob Choi,
Objectives: To evaluate the efficacy and tolerability of donepezil in patients with Binswanger type subcortical vascular dementia.; Methods: Patients (n = 34, mean age = 71.8 + 7.12) with Binswanger type subcortical vascular dementia from 8 multicenter, according to clinical and neuroradiological working criteria, were selected to receive donepezil 5 mg/day (n = 2) or […]
Phase II crossover trial of varenicline in mild-to-moderate Alzheimer’s disease
Kim, Seong Yoon,
Choi, Seong Hye,
Rollema, Hans,
Schwam, Elias M.,
McRae, Tom,
Dubrava, Sarah,
Jacobsen, Janice
Background: Evidence supports a role of α4β2 receptors in Alzheimer’s disease (AD).; Methods: This Korean, multicenter, double-blind, two-period (6 weeks each), crossover study randomized participants to the order in which they received varenicline (1 mg twice daily) and placebo. Assessments included AD Assessment Scale-Cognitive Subscale (ADAS-Cog) 75, Neuropsychiatric Inventory (NPI), adverse events (AEs) and Columbia-Suicide […]
Cognitive effects of reducing anticholinergic drug burden in a frail elderly population: a randomized controlled trial
Kersten, H.,
Molden, E.,
Tolo, I. K.,
Skovlund, E.,
Engedal, K.,
Wyller, T. B.
Background: Observational studies report a relationship between anticholinergic drug scale (ADS) score and cognitive function. This study investigated whether a reduced ADS score improved cognitive function in a frail elderly population.; Methods: This randomized, controlled, single-blinded trial, recruited long-term residents with an ADS score of greater than or equal to 3 from 22 nursing homes […]
Omega-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer’s disease: the omega-3 Alzheimer’s disease study
Faxén Irving, Gerd,
Freund-Levi, Yvonne,
Eriksdotter-Jönhagen, Maria,
Basun, Hans,
Brismar, Kerstin,
Hjorth, Erik,
Palmblad, Jan,
Vessby, Bengt,
Vedin, Inger,
Wahlund, Lars-Olof,
Cederholm, Tommy
Objectives: To study the effects of omega (Omega)-3 fatty acid (FA) supplements on weight and appetite in patients with mild to moderate Alzheimer’s disease (AD) in relation to inflammatory biomarkers and apolipoprotein E epsilon4 (APOEepsilon4).; Design: Randomized, double-blind, placebo-controlled trial.; Setting: Specialist memory clinics in the Stockholm catchment area.; Participants: Two hundred four patients (aged […]